Conditions: Liver Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 45
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: bevacizumab [Avastin] intervention 2: capecitabine [Xeloda]
Intervention descriptions: intervention 1: 7.5mg/kg iv on day 1 of each 3 week cycle. intervention 2: 1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.

Protocol document: